75%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
75%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
75%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
75%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Cara Therapeutics Inc
Closed
Sector Healthcare
4.99 -0.8
Overview
Share price change
24h
Min
4.99
Max
5.16
Income | -12M |
|---|---|
Sales | 1.6M 2.6M |
EPS | -0.118 |
Profit margin | -488.106 |
Employees | 55 |
EBITDA | 4.2M -10M |
Market Cap | -23M 22M |
|---|---|
Previous open | 5.79 |
Previous close | 4.99 |
News Sentiment
By Acuity
63%
37%
348 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Cara Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cara Therapeutics Inc Forecast
Sentiment
By Acuity
348 / 393 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Cara Therapeutics Inc
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
